Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2629380 | 0.76 | TGFBR1 (0.43) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL27389547 | 0.74 | DYRK1A (0.40) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL5487376 | 0.74 | DYRK1A (0.40) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL5488750 | 0.74 | DYRK1A (0.47) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL11266549 | 0.74 | DYRK1A (0.40) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL29748586 | 0.74 | DYRK1A (0.37) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL19184892 | 0.70 | MET (0.41) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL408627 | 0.70 | DYRK1A (0.53) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL24574129 | 0.69 | DYRK1A (0.37) | DYRK1AKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL24574363 | 0.69 | DYRK1A (0.37) | DYRK1AKEAP1MEN1CYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146049-A1 | SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2026-05-28 | — | — | US | disclosed |
| EP-4741392-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | Shenzhen TargetRx Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-12612410-B2 | Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4658659-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2025-12-10 | — | — | EP | disclosed |
| EP-4630402-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-10-15 | — | — | EP | disclosed |
| EP-3321268-B1 | BICYCLIC HETEROARYL DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2025-06-04 | — | — | EP | disclosed |
| CN-120040420-A | Heterocyclic-pyrazole amine derivatives, preparation method thereof and application thereof in resisting tubercle bacillus infection | 中国医学科学院医药生物技术研究所 | 2025-05-27 | — | — | CN | disclosed |
| US-20250154144-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDRENS HOSPITAL MED CT (US) | 2025-05-15 | — | — | US | disclosed |
| WO-2008099000-A2 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-21 | — | — | WO | disclosed |
| US-20080182849-A1 | Certain Heterocyclic Substituted Imidazo[1,2-A]Pyrazin-8-Ylamines And Methods Of Inhibition Of Bruton's Tyrosine Kinase By Such Compounds | CURRIE KEVIN S | 2008-07-31 | — | — | US | disclosed |
| WO-2008078091-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
| US-7393848-B2 | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds | CGI PHARMACEUTICALS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-20050101604-A1 | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of bruton's tyrosine kinase by such compounds | GILEAD CONNECTICUT, INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2005005429-A1 | CERTAIN HETEROCYCLIC SUBSTITUTED IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES AND METHODS OF INHIBITION OF BRUTON’S TYROSINE KINASE BY SUCH COMPOUNDS | CELLULAR GENOMICS, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004085409-A2 | COMPOUNDS AND LIBRARIES OF PYRIDINES, PYRAZINES, IMIDAZO[1,2-A]PYRAZINES AND 1H-IMIDAZO[4,5-B]PYRAZIN-2-ONES AND FIRST AND SECOND MEDICAL USES THEREOF | BIOFOCUS DISCOVERY LTD (GB) | 2004-10-07 | — | — | WO | disclosed |
| US-5028605-A | Antispasmodic, bronchodilators, uterine relaxants, cardiac analeptics, neurosedatives | L'UNIVERSITE DE MONTPELLIER I (FR) | 1991-07-02 | — | — | US | disclosed |
| EP-0348392-A1 | 8-ALKYLAMINOIMIDAZO[1,2-A]PYRAZINES AND DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | Université Montpellier I (FR) | 1990-01-03 | — | — | EP | disclosed |
| WO-1988004298-A1 | 8-ALKYLAMINOIMIDAZO[1,2-A]PYRAZINES AND DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1988-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | CLK3, CLK2, CLK1 | DYRK1A 18/4885KEAP1 2221/4885MEN1 1236/4885 |
| US-20050101604-A1 | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of bruton's tyrosine kinase by such compounds | BTK, SYK, LYN | DYRK1A 400/4885KEAP1 3203/4885MEN1 2893/4885 |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | DYRK1A 2830/4885KEAP1 912/4885MEN1 3710/4885 |
| US-12612410-B2 | Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof | FLT3, IRAK3, IRAK2 | DYRK1A 1980/4885KEAP1 1096/4885MEN1 2243/4885 |
| US-20250154144-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK1, IRAK3 | DYRK1A 694/4885KEAP1 1194/4885MEN1 908/4885 |
| US-20080182849-A1 | Certain Heterocyclic Substituted Imidazo[1,2-A]Pyrazin-8-Ylamines And Methods Of Inhibition Of Bruton's Tyrosine Kinase By Such Compounds | BTK, SYK, LYN | DYRK1A 372/4885KEAP1 3269/4885MEN1 2815/4885 |
| US-20260146049-A1 | SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, HRAS | DYRK1A 3984/4885KEAP1 260/4885MEN1 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.